方盛制药：吲哚布芬片获《药品注册证书》

Core Viewpoint - Fangsheng Pharmaceutical has received approval from the National Medical Products Administration for the production of Indobufene Tablets, enhancing its product line in cardiovascular medications and increasing market competitiveness, although short-term sales impact on performance is expected to be limited [1] Summary by Categories Product Approval - The company has been granted a drug registration certificate for Indobufene Tablets, with a specification of 0.2g and a validity period until November 3, 2030 [1] Research and Development Investment - Cumulative R&D investment for the project has reached approximately 28.72 million yuan [1] Sales Performance - In the first half of 2025, the total sales for the drug in hospitals and retail pharmacies are projected to be 1.192 billion yuan and 266 million yuan, respectively [1] Market Impact - The approval enriches the company's cardiovascular medication product line and enhances its market competitiveness, but various factors may influence sales performance, leading to a limited short-term impact on overall performance [1]